- A German firm whose main product is derived from the saliva of the vampire bat is looking to raise more than 70m euros
- Its main drug, desmoteplase, is based on a protein in the bat's saliva
- The firm, Paion, said that it hoped to sell 5 million shares for 11-14 euros a share
